These days, it seems more and more testosterone supplement risks lawsuits are rearing their heads. According to a recent study published by the Journal of the American Medical Association, there are a number of strong theories suggesting that testosterone therapy given to men that are otherwise healthy can lead to the risk of heart attack and strokes. It seems these assertions have largely been proven true.
For instance, just take the latest findings regarding AndroGel. It has been shown to increase arterial plaque in many men, especially those that are older. A detailed report from late February of 2017 held nothing back in describing just how dangerous many testosterone supplements can be. Even with FDA approval, many of the products that are flooding the market in response to the widespread “low T” problem have problematic ingredients that may ultimately do more harm than good.
And yet, sales are skyrocketing. Testosterone issues are rampant enough for a large industry to have been built around its treatments. Many manufacturers are reaching significant market saturation through key advertising strategies that help them get around the need to offer well tested products. Certain conditions such as “hypogonadism” have been thrown around liberally to apply to virtually any issue associated with low testosterone levels. In short, there’s a troubling “one size fits all” approach going on that isn’t exactly admirable.
Of course, testosterone levels will naturally drop with age. A wide variety of men begin suffering from it at one point or another. That said, not every male with diminishing T levels has the same overall health. A fairly active and fit man in his 50s might buy into the idea that he needs one of the AndroGel “Low T” style products. Since they are seldom fit for otherwise healthy individuals, the door is left wide open to potential harm.
It’s been known for some time that there are potential cardiovascular risks that may come as a side effect of testosterone supplement risks. Even so, the original information detailed by the United States’ Food & Drug Administration gave the impression that nearly all testosterone issues pertained to hypogonadism as described above. As such, most seemed that the benefits to taking supplements were merited.
In the wake of this, many testosterone supplement manufacturers have been able to market themselves quite aggressively. The Journal of the American Medical Association’s study was conducted in order to help put the entire issue of benefits and potential testosterone supplement risks pertaining to testosterone therapy to bed. Several key questions were asked, including:
- What are the side effects of the treatment?
- How much does it increase the risk of heart attack?
- Are treatments for older men associated with a drop in the volume of their coronary arterial plaque?
The research suggests that the level of non-calcified coronary arterial plaque increased quite a bit in participants aged 64 years old and beyond. Placebos were tested as well, and those that received the real supplements had plaque volumes of 41 mm more. Half of the men were given mere placebos, whereas the others were treated with AndroGel.
The increase in the arterial plaque has been apparent after just a year of taking the product. It’s clear that more research still needs to be done, however, and the same sentiment has been echoed by the researchers. Even so, the initial results do present some room for worry.
At the present time, there are around 6,000 different lawsuits dealing with testosterone supplements and treatments specifically. Numerous aggressive and dangerous testosterone supplement risks are being brought to the forefront, two of the most common of which happen to be stroke and heart attacks. Among the frenzy, AndroGel is also set to receive quite an up-close review. With luck, the whole matter will lead to some definite answers that will set the matter of testosterone treatments back on course.